Expectations of side effects evoked by perceptual characteristics of curatives and their psychological background

Cel: A gyogyszermellekhatasok egy resze nem-specifikus eredetű (nocebo-hatas), s ezen belul is reszben a gyogyszerek perceptualis jellemzői (szin, meret stb.) altal kivaltott elvarasokra, reszben egyes hajlamosito szemelyisegvonasokra vezethető vissza. Jelen munka celja e tenyezők es a vart mellekhatasok kozotti kapcsolatok vizsgalata volt. Modszer: A resztvevők (118 alsoeves egyetemi hallgato) 6 kulonboző szinű/meretű tabletta eseten 10 gyakori nem-specifikus gyogyszermellekhatas jelentkezesenek valoszinűseget becsultek meg, valamint szemelyiseg-kerdőiveket (STAI-T, LOT-R, PHQ-15, SSAS) toltottek ki. Eredmenyek: A kulonboző kinezetű tablettak mind a 10 mellekhatas tekinteteben szignifikansan kulonboztek egymastol, a vart mellekhatasok sulyossagat leginkabb a szomatizacios hajlam (Szubjektiv Testi Tunetek 15 kerdőiv, PHQ-15) es a szomatoszenzoros amplifikacio (SSAS) alapjan lehetett előre jelezni. Az utvonalelemzes alapjan a vonasszorongas (STAI) es a nem hatasa csak kozvetetten, a fenti ket tenyezőn kere...

[1]  Ferenc Köteles,et al.  Placebo és személyiség – a primitívtől a megküzdőig II. , 2008 .

[2]  Ferenc Köteles,et al.  Placebo és személyiség - a primitívtől a megküzdőig: I. A placebo-reszponder személyiség , 2008 .

[3]  Andrew L. Geers,et al.  Further evidence for individual differences in placebo responding: an interactionist perspective. , 2007, Journal of psychosomatic research.

[4]  Edgar Erdfelder,et al.  G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.

[5]  B. Olshansky.  Placebo and nocebo in cardiovascular health: implications for healthcare, research, and the doctor-patient relationship. , 2007, Journal of the American College of Cardiology.

[6]  Máté Szondy.  Optimizmus és egészség , 2006 .

[7]  Jürgen Hoyer,et al.  Separating Optimism and Pessimism: a Robust Psychometric Analysis of the Revised Life Orientation Test (lot–r) the Internal Structure of the Revised Life Orientation Test (lot , 2022 .

[8]  Barna Konkolÿ Thege,et al.  AZ ÉSZLELT STRESSZ KÉRDŐÍV (PSS) MAGYAR VERZIÓJÁNAK JELLEMZŐI , 2006 .

[9]  E. Raufaste,et al.  Configural instability of data from the Life Orientation Test—Revised , 2006 .

[10]  K. Kroenke.  Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. , 2006, Journal of psychosomatic research.

[11]  Richard Brown.  Medically unexplained symptoms , 2006 .

[12]  R. Bootzin,et al.  Understanding placebo, nocebo, and iatrogenic treatment effects. , 2005, Journal of clinical psychology.

[13]  Andrew L. Geers,et al.  Reconsidering the role of personality in placebo effects: dispositional optimism, situational expectations, and the placebo response. , 2005, Journal of psychosomatic research.

[14]  E. Raufaste,et al.  Dimensionality of the Revised Life Orientation Test and the status of filler items , 2003 .

[15]  D. Moerman.  Meaning, Medicine, and the “Placebo Effect”: Measurement and its ambiguities , 2002 .

[16]  R. Spitzer,et al.  The PHQ-15: Validity of a New Measure for Evaluating the Severity of Somatic Symptoms , 2002, Psychosomatic medicine.

[17]  L. F. Barrett,et al.  Feeling your body or feeling badly: evidence for the limited validity of the Somatosensory Amplification Scale as an index of somatic sensitivity. , 2001, Journal of psychosomatic research.

[18]  G. Tollefson,et al.  No gender differences in placebo responses of patients with major depressive disorder , 2001, Biological Psychiatry.

[19]  A. Ströhle.  Increased response to a putative panicogenic nocebo administration in female patients with panic disorder. , 2000, Journal of psychiatric research.

[20]  P. Spinhoven,et al.  Somatization and somatosensory amplification in psychiatric outpatients: an explorative study. , 1997, Comprehensive psychiatry.

[21]  J. Kleijnen,et al.  Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness , 1996, BMJ.

[22]  Michael W. Bridges,et al.  Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. , 1994, Journal of personality and social psychology.

[23]  James W. Pennebaker,et al.  Psychological Bases of Symptom Reporting: Perceptual and Emotional Aspects of Chemical Sensitivity , 1994, Toxicology and industrial health.

[24]  J. Ferguson.  Alprazolam-XR: Patient Acceptability, Safety, and Tolerability , 1993, Psychiatric Annals.

[25]  P. Cleary,et al.  The amplification of somatic symptoms. , 1988, Psychosomatic medicine.

[26]  A. Barsky.  Nonpharmacologic aspects of medication. , 1983, Archives of internal medicine.

[27]  A. Barsky.  Patients who amplify bodily sensations. , 1979, Annals of internal medicine.

[28]  C. Larousse,et al.  Methodology and results of a survey of adverse reactions to a drug in private practice , 1977, European Journal of Clinical Pharmacology.

[29]  M. D. Epstein,et al.  The placebo effect. A neglected asset in the care of patients. , 1975 .

[30]  A. Cattaneo,et al.  Sedative effects of placebo treatment , 1970, European Journal of Clinical Pharmacology.

[31]  K. Schapira,et al.  Study on the Effects of Tablet Colour in the Treatment of Anxiety States , 1970, British medical journal.

[32]  R. Philp,et al.  A controlled clinical trial using placebos in normal subjects: a teaching exercise. , 1967, Canadian Medical Association journal.

[33]  K. Rickels.  Some comments on non-drug factors in psychiatric drug therapy. , 1965, Psychosomatics.

[34]  D. M. Green.  PRE-EXISTING CONDITIONS, PLACEBO REACTIONS, AND "SIDE EFFECTS". , 1964, Annals of internal medicine.

[35]  W. Gantt,et al.  Some implications of conditional reflex studies for placebo research. , 1957, The American journal of psychiatry.

[36]  A. Ralston.  Side effect , 2003 .

[37]  C. Helman.  Chapter 1 – Placebos and nocebos: the cultural construction of belief , 2001 .

[38]  E. Uhlenhuth,et al.  Medication side effects in anxious patients: negative placebo responses? , 1998, Journal of affective disorders.

[39]  Irving Kirsch,et al.  Specifying nonspecifics: Psychological mechanisms of placebo effects. , 1997 .

[40]  H. Benson,et al.  Harnessing the power of the placebo effect and renaming it "remembered wellness". , 1996, Annual review of medicine.

[41]  G. Klerman,et al.  The somatosensory amplification scale and its relationship to hypochondriasis. , 1990, Journal of psychiatric research.

[42]  James W. Pennebaker,et al.  The psychology of physical symptoms , 1982 .

[43]  G. Claridge.  Drugs and human behaviour , 1970 .

[44]  Glaser Em,et al.  Evidence for a non-specific mechanism of habituation. , 1953 .